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Available online 9 January 2011Daptomycin is a lipopeptide antibiotic that kills Gram-positive bacteria by membrane depolarization. While it
has long been assumed that the mode of action of daptomycin involves the formation of membrane-
associated oligomers, this has so far not been experimentally demonstrated.We here use FRET between native
daptomycin and an NBD-labeled daptomycin derivative to show that such oligomerization indeed occurs. The
oligomers are observed in the presence of calcium ions onmembrane vesicles isolated from Bacillus subtilis, as
well as on model membranes containing the negatively charged phospholipid phosphatidylglycerol. In
contrast, oligomerization does not occur on membranes containing phosphatidylcholine only, nor in solution
at micromolar daptomycin concentrations. The requirements for oligomerization of daptomycin resemble
those previously reported for antibacterial activity, suggesting that oligomerization is necessary for the
activity..
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Daptomycin is a lipopeptide antibiotic produced by Streptomyces
roseosporus. It is a cyclic molecule with a decanoyl fatty acid side chain
attached to the exocyclic, N-terminal single tryptophan residue [1]. It
contains thirteen amino acid residues, some of which are non-
standard ones, including a kynurenine and an ornithine (Fig. 1).
Daptomycin possesses rapid bactericidal activity against a broad
spectrum of Gram-positive pathogens [2,3]. It is active against difﬁcult
pathogens such as vancomycin-resistant staphylococci and entero-
cocci [4]. Daptomycin is approved for clinical use in the treatment of
Staphylococcus aureus, including MRSA, in bacteremia, right-sided
endocarditis, and complicated skin and skin structure infections.
The bactericidal activity of daptomycin is mediated by membrane
permeabilization and depolarization [5]. It is calcium-dependent and
applies to both resting and proliferating cells [6]. Susceptibility of
bacteria to daptomycin is correlated with the membrane content of
phosphatidylglycerol; it is decreased by mutations that promote the
conversion of phosphatidylglycerol to lysylphosphatidylglycerol [7].
On bacterial cell membranes, ﬂuorescently labeled daptomycin
localizes to phosphatidylglycerol-rich membrane areas [8].
Membrane-permeabilizing proteins and peptides commonly form
oligomeric structures on the target membrane. Daptomycin oligomers
have been detected in solution at relatively high (0.75 mM) concen-
trations, and the formation of oligomers prior to membrane binding
has been interpreted as an integral step in daptomycin activity [9].However, there is as yet no experimental evidence of daptomycin
oligomers on lipid membranes.
In the present study, we have examined the oligomerization of
daptomycin both in solution and on membranes. To this end, we used
daptomycin derivatives ﬂuorescently labeled with NBD (7-nitro-
2,1,3-benzoxadiazol) and with Alexa Fluor 350. Oligomerization was
detected through ﬂuorescence resonance energy transfer (FRET) as
well as through the self-quenching of NBD ﬂuorescence. We detected
oligomerization on liposome membranes containing phosphatidyl-
glycerol, combined with either phosphatidylcholine (PC) or phos-
phatidylethanolamine (PE) plus cardiolipin (CL), as well as on
membrane vesicles prepared from Bacillus subtilis (ATCC 6633) cells.
In contrast, no oligomerization was observed with liposomes contain-
ing phosphatidylcholine alone, nor in solution at daptomycin
concentrations similar to those required for antibacterial activity.
The requirements that we ﬁnd for oligomerization correlate with
those for membrane permeabilization and bacterial susceptibility
[1,7], suggesting that the membrane lesion is caused by the
daptomycin oligomer.
2. Materials and methods
2.1. Preparation of NBD–daptomycin
Unlabeled daptomycin was supplied by Cubist Pharmaceuticals
Inc. (Lexington, MA, USA). NBD-Cl (4-chloro,7-nitro-2,1,3-benzox-
adiazol, or 7-chloro-4-nitrobenzofurazan) was obtained from Fluka
(Fluka, St. Louis, MO, USA). All other chemicals were obtained from
Bioshop (Burlington, ON) and were of analytical grade. Daptomycin
(0.6 mM) was dissolved in 50 mM sodium borate buffer (pH 8)
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Fig. 1. Structure of daptomycin and of the labeled derivatives used in this study. The decanoyl residue is attached to the exocyclic N-terminal tryptophan residue. The ornithine
residue carries the sole free amino group, which is free in daptomycin (R=H) but labeled with the ﬂuorophores NBD or Alexa Fluor 350 in the two derivatives. The kynurenine
residue possesses intrinsic ﬂuorescence.
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trile. 300 μl of daptomycin solution and 100 μl of NDB-Cl solution
were mixed in a reaction vial and incubated at 60 C for two hours. The
mixture was then cooled in an ice water bath for 2 min, and ﬁnally
acidiﬁed by adding 400 μl of acetic acid (50 mM) to stop the labeling
reaction.
An HPLC system (Waters 625 LC) was used to purify the labeled
daptomycin on a reversed-phase column (Agilent, Eclipse XDB-C8,
150×4.6 mm). The mobile phase was 20 mM ammonium acetate (pH
5.5) with an acetonitrile gradient from 30 to 40% and a ﬂow rate of
1 ml/min [10,11]. Fractions were examined by spectrophotometry,
spectroﬂuorometry (see below), and mass spectrometry using a
Micromass Q-TOF Ultima GLOBAL mass spectrometer. The molecular
weight of the puriﬁed NBD-labeled daptomycin determined by mass-
spectrometry was 1783.7 Da. This corresponds to the expected
molecular weight of 1784 Da for the stoichiometric adduct (Fig. 1).
To determine the concentration, we assumed a molar extinction
coefﬁcient at 476 nm of 24,000 as previously determined for the NBD-
adduct of alanine [12].
2.2. Preparation of Alexa Fluor 350–daptomycin
Daptomycin triﬂuoroacetate salt (20.34 mg, 0.013 mmol) was
dissolved in DMF at 0 °C. Alexa Fluor-350 succinimide (Molecular
Probes, 5 mg, 0.013 mmol) was added and stirred for 5 min. Hünig's
base (N,N-diisopropyl-ethylamine) was added and the reaction
mixture was stirred for 60 min. The reaction solution was poured
into a ﬂask containing cold diethylether (35 ml), which led to pre-
cipitation. The precipitate was collected by centrifugation (3500 rpm
for 5 min), washed with diethyl ether and again recovered by cen-
trifugation. The material was dried under high vacuum then puriﬁed
via HPLC.
2.3. Preparation of large unilamellar vesicles (LUV) and of bacterial
membrane vesicles
1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyr-
istoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (DMPG), 1-palmitoyl-
2-oleoyl-sn-glycerol-3-phosphoethanol (POPE), 1,2-dioleoyl-sn-glycerol-
3-phospho-(1-rac-glycerol) (DOPG), and1,3-bis[1,2-dioleoyl-sn-glycero-
3-phospho]-sn-glycerol (cardiolipin; TOCL) were purchased from
Avanti Polar Lipids, Inc. (Alabaster, AL, USA). The required amounts of
DMPC and DMPG, or of POPE, POPG and cardiolipin, were weighted,dissolved in chloroform and transferred to a round-bottom ﬂask. The
solvent was evaporated with nitrogen and the resulting lipid ﬁlms
further dried under vacuum for three hours. The lipids were then
suspended inHEPES buffer (20 mM, pH7.4) containing150 mMsodium
chloride. Finally, the suspension was extruded 10–15 times through
100 nm polycarbonate ﬁlters, using a nitrogen-pressurized extrusion
device [13]. The liposomes were employed in the ﬂuorescence
experiments at a ﬁnal concentration of 250 μM of lipid. Bacterial
membraneswere prepared from Bacillus subtilisATCC 6633, grown in LB
broth, according to the procedure described in Ref. [14], except that the
Potter homogenization was omitted, and the membranes were treated
with a probe sonicator on ice for 2 min instead. Again as in [14], the
membrane vesicles obtained were quantitated by assaying for mem-
brane protein using the Lowry method.
2.4. Antibacterial activity test for daptomycin and NBD–daptomycin
NBD–daptomycin and unlabeled daptomycin were tested for
antibacterial activity by broth dilution. LB broth was supplemented
with calcium (5 mM) and daptomycin and NBD–daptomycin, respec-
tively, at concentrations of 10, 5, 3, 2, 1.5, and 1 μg/ml. Growth
controls without antibiotic were also included. Each tube was
inoculated with Bacillus subtilis ATCC 6633 and incubated overnight
at 37 °C. Growth inhibition was evaluated visually by turbidity.
2.5. Fluorescence studies
Emission spectra and time-based scans were acquired on a Quanta-
Master 4 spectroﬂuorimeter (Photon Technology International, London,
ON). Kynurenine ﬂuorescence was excited at 365 nm and the emission
recorded from 400 to 600 nm. NBD ﬂuorescence was excited at 465 nm
and the emission recorded from 490 to 600 nm. Alexa Fluor 350 was
excited at 350 nm and emission recorded from 400 to 600 nm.
Bandpasses for excitation and emission were between 2 and 5 nm.
The steady state spectra shownwere acquired at 37 °C; spectra acquired
at room temperature were virtually indistinguishable.
The concentrations of calcium, where present, were 200 mM with
PC liposomes and 5 mM in all other cases. For the calculation of the
Förster radius [15] for kynurenine and NBD on PC/PG membranes, the
quantum yield of kynurenine (0.039) was obtained by comparison to
a quinine sulfate standard. The spectral overlap integral for donor
emission and acceptor absorbance was determined from the absorp-
tion spectrum of NBD–daptomycin (see Fig. 2) and the emission
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Fig. 2. Absorbance (dashed lines) and ﬂuorescence emission (solid lines) spectra of
(A) daptomycin, (B) Alexa Fluor 350–daptomycin and (C) NBD–daptomycin. The
kynurenine residue in daptomycin causes the absorbance peak around 360 nm and the
emission peak at 460 nm. The absorbance and emission peaks of Alexa Fluor 350–
daptomycin occur in similar positions. NBD–daptomycin has an absorbance peak at
475 nm that overlaps the emission peaks of the other two; this overlap causes
ﬂuorescence resonance energy transfer (FRET) from daptomycin and Alexa Fluor 350–
daptomycin to NBD–daptomycin. Direct excitation at 475 nm allows the observation of
NBD ﬂuorescence alone.
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Fig. 3. Fluorescence of NBD–daptomycin (0.91 μM) incubated with liposomes, with or
without calcium. The liposomes consisted of phosphatidylcholine and phosphatidyl-
glycerol (PC/PG) or phosphatidylcholine only (PC). The excitation wavelength was
465 nm. The two samples without calcium are scaled to the same maximum intensity;
the two samples containing calciumwere scaled accordingly, so that the relative gain in
intensity upon addition of calcium can be compared.
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of calcium, with correction for the wavelength-dependent sensitivity
of the spectroﬂuorimeter. For the orientation factor κ2, a value of 2/3
was used, which applies in the commonly assumed case of randomly
distributed orientations of donor and acceptor [15].
Fluorescence lifetimemeasurements were performed on a FluoTime
100 Lifetime spectrometer using a P-C-370 diode laser light source
(PicoQuant, Berlin, Germany). The lifetime instrument did not have a
thermostatted cell holder, and therefore lifetime measurements were
performedonly at roomtemperature. Kynurenineemissionwas isolated
using a 460±10 nm band pass ﬁlter (Melles-Griot, Brossard, QC).
Experimental decayswere numerically ﬁt with three exponentials,with
resulting χ2 values typically below 1.2. From these three components,
average lifetimes were calculated according to the equation
〈τ〉 =
∑αiτi
∑αiwereαi represents the amplitude at time zero and τi the lifetime of the
ith component.3. Results
3.1. Characterization of NBD–daptomycin
The absorption and emission spectra of puriﬁed NBD–daptomycin
are shown in Fig. 2C. The main absorbance peak of NBD–daptomycin
occupies a very similar spectral position as the kynurenine ﬂuores-
cence emission peak of unlabeled daptomycin (Fig. 2A). This spectral
overlap indicates that ﬂuorescence energy transfer (FRET) will occur
from kynurenine to NBD. Indeed, when the kynurenine residue in
NBD–daptomycin is excited (at 365 nm), the only ﬂuorescence peak
observed is that typical of NBD, indicating that all photons absorbed
by kynurenine are transferred to NBD through FRET.
The antibacterial activity ofNBD–daptomycinwas identical to that of
unmodiﬁed daptomycin (MIC=3 μg/ml). Alexa Fluor 350–daptomycin
was found to be 8- to 16-fold less active than unlabeled daptomycin.3.2. Calcium-dependent membrane interaction of daptomycin and
NBD–daptomycin
It has previously been reported that the kynurenine ﬂuorescence
of daptomycin increases in intensity and undergoes a blue shift upon
interaction with calcium and negatively charged phospholipid
membranes, composed of phosphatidylcholine (PC) and phosphati-
dylglycerol (PG). Such changes are observed with many ﬂuorophores
upon transition from a more polar environment to a less polar one,
such as the hydrophobic interior of a lipid bilayer. A similar change in
the ﬂuorescence signal also occurs on neutral (PC) membranes.
However, the gain in intensity is less, and the position of the
ﬂuorescence peak is different from that observed on PC/PG mem-
branes, suggesting a different environment of the kynurenine residue
and, hence, a different conformation of the daptomycin molecule
[16,17]. Also note that with PC alone the ﬂuorescence change occurs
only at far higher concentrations of calcium.
NBD–daptomycin also gains in ﬂuorescence intensity in the
presence of membranes and calcium (Fig. 3). The ﬂuorescence gain
appears larger on PCmembranes than on PC/PGmembranes, although
the opposite is actually true after NBD self-quenching on PC/PG
membranes is accounted for (compare Fig. 5, below). The spectral
difference indicates a different environment of the labeled residue
(ornithine) on the two types of membranes.
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The efﬁciency of FRET is distance-dependent, and it can approach
100% if the distance between the donor and an acceptor is well below
the Foerster radius (R0). For kynurenine in unlabeled daptomycin,
bound to DMPC/DMPGmembranes, as the donor and NBD–daptomycin
as the acceptor,we estimated R0 as 2.7 nm(seeMaterials andmethods).
Since the daptomycin molecule is smaller than that, formation of
hybrid oligomers from daptomycin and NBD–daptomycin should
cause FRET from the unlabeled to the labeled species. However, some
degree of FRET should also occur without oligomerization, due to the
proximity of some donors and acceptors when both are randomly
distributed in the membrane plane [18].
To distinguish between these two effects, we measured FRET at
different ratios of daptomycin to NBD–daptomycin, while keeping the
absolute concentration of NBD–daptomycin constant. The rationale of
this experiment is as follows: if donors (daptomycin) and acceptors
(NBD–daptomycin) remain monomeric and separate, the efﬁciency of
FRET, as measured by the reduction of donor emission, varies only
with the acceptor concentration but not the donor concentration [18];
hence, the extent of FRET should not vary between the samples in our
experiment. On the other hand, if donor and acceptor form hybrid
oligomers, the probability for a donor to end up within close
proximity to an acceptor molecule will increase with the relative
amount of acceptors present. Therefore, at a ﬁxed concentration of
NBD–daptomycin, the efﬁciency of FRET should increase with
decreasing concentration of unlabeled daptomycin.
FRET can be observed both with time-resolved (Fig. 4A) and with
steady-state ﬂuorescence measurements (Fig. 4B). In the time-
resolved experiment, an increase in FRET corresponds to a decrease
in the donor's excited state lifetime. Fig. 4A shows that, on DMPC
membranes, the lifetime is almost the same at donor-acceptor ratios
of 16:1 and 1:1, indicating no change in FRET and therefore no
oligomerization. In contrast, on PC/PG membranes, the same change
in the donor to acceptor ratio causes a fourfold reduction in the
kynurenine lifetime, indicating that oligomerization occurs on these
membranes.
Also shown for comparison are the lifetimes of unlabeled
daptomycin alone. On both PC and PC/PGmembranes, the kynurenine
lifetime is signiﬁcantly longer than with those samples that contain
the equivalent amount of donor but with NBD–daptomycin present.
This difference reﬂects FRET between molecules that are not part of
the same oligomers, and thus is not an indication of oligomerization.
In steady-state ﬂuorescence spectra (Fig. 4B), the kynurenine peak
was much lower with mixtures of daptomycin and NBD–daptomycin
than with daptomycin only, indicating extensive FRET. This FRET0
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Fig. 4. FRET experiments on the oligomerization of daptomycin. A: Kynurenine ﬂuorescence l
with saturating concentrations of calcium. The concentration of NBD–daptomycin was 1.
indicated molar ratios. The two unconnected data points were obtained with unlabeled dap
daptomycin (0.91 μM), either alone or together, on DMPC/DMPGmembranes. In the premixe
and calcium. In the sequential sample, daptomycin and calcium were added to the membrashould occur in part within oligomers and in part between oligomers.
When daptomycin and NBD–daptomycin were applied to PC/PG
membranes sequentially, with time allowed for the oligomerization of
NBD–daptomycin before addition of the daptomycin, the drop in
donor intensity was reduced by half. The most likely interpretation is
that in this sample the labeled and the unlabeled molecules had
formed separate oligomers, thus removing the component of FRET
that occurred within hybrid oligomers, and leaving only the
component between separate oligomers. The spectra of such samples
did not change substantially over two hours, suggesting that most
oligomers remained intact over this length of time.
3.4. Detection of oligomerization by NBD self-quenching; oligomerization
on bacterial membranes
Like many other ﬂuorophores, NBD undergoes self-quenching at
high concentration, which likely involves FRET from monomeric NBD
molecules to non-ﬂuorescent aggregated pairs [19]. In oligomers
consisting of NBD–daptomycin only, the local concentration of NBD
groups, and thus the likelihood of aggregation will be higher than in
mixed oligomers with unlabeled daptomycin.
Therefore, the ﬂuorescence signal of the same amount of NBD–
daptomycin – after direct excitation at 465 nm, eliminating any FRET
from kynurenine – should increase in the presence of unlabeled
daptomycin. This is indeed observedwith PG/PCmembranes (Fig. 5A).
On the other hand, without oligomerization, the extent of self-
quenching should be unaffected by the presence of unlabeled
daptomycin, and therefore the NBD-ﬂuorescence should remain
unchanged. This is indeed the case with PC alone (Fig. 5B), which
conﬁrms that oligomerization does not occur on these membranes.
The composition of Bacillus cereus and Bacillus subtilis cell
membranes has been modeled with liposomes consisting of cardio-
lipin (TOCL, 17%), phosphatidylglycerol (DOPG, 40%) and phosphati-
dylethanolamine (POPE, 43%) [20,21]. On such liposome membranes,
oligomerization is again observed (Fig. 5C). The same applies to
membrane vesicles prepared from Bacillus subtilis bacterial cells
(Fig. 5D).
3.5. Daptomycin does not form oligomers in solution at antimicrobially
active concentrations
It has been previously reported that daptomycin forms oligomers
in solution in the presence of calcium. This was observed by both NMR
[9,16] and ultracentrifugation [22], and accordingly the concentration
of daptomycin was in the millimolar range. Fluorescence allows the
observation of oligomerization at much lower concentrations, similar0
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Fig. 5. Fluorescence of NBD–daptomycin (0.91 μM) on (A) DMPC/DMPG liposomes, (B) PC liposomes, (C) POPE/DOPG/TOCL liposomes and (D) Bacillus subtilis membrane vesicles,
without (solid lines) or with (dashed lines) a fourfold excess with unlabeled daptomycin. Since the excitation wavelength (465 nm) was outside the absorbance spectrum of
kynurenine, differences in intensity are not due to FRET from kynurenine but to NBD self-quenching within oligomers.
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very low ﬂuorescence intensity in aqueous solution, we here used
daptomycin labeled with Alexa Fluor 350, which has a high intensity
in both polar and apolar environments. The spectral positions of
excitation and emission of Alexa Fluor 350 are such that this labeled
derivative can again be combined with NBD–daptomycin in FRET
experiments [23].
Fig. 6A shows the interaction of Alexa Fluor 350–daptomycin and
NBD–daptomycin in solution and on PC/PG membranes, in the
presence of calcium. On membranes, Alexa ﬂuorescence is strongly
reduced by FRET to NBD, which is consistent with oligomerization.
In contrast, no FRET occurs when the membranes are missing. This0
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FRET in the sample with NBD–daptomycin but without calcium indicates absence of membindicates that no oligomerization is happening; calcium-mediated
oligomerization in solution therefore is restricted to much higher
concentrations and not germane to the antimicrobial effect of
daptomycin (without NBD–daptomycin, the ﬂuorescence of Alexa
Fluor 350–daptomycin on membranes is still somewhat lower than
without membranes, suggesting that Alexa Fluor 35o is subject to
some degree of self-quenching upon oligomerization, too).
Fig. 6B shows the interaction of Alexa Fluor 350–daptomycin and
NBD–daptomycin on PC membranes, with and without calcium. With
calcium, there is FRET, albeit less than on PC/PG membranes. Since no
oligomerization occurs on PC, this FRET is due tomembrane binding of
both Alexa Fluor 350–daptomycin and NBD–daptomycin; membrane0
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solution. No FRET occurs with PC but without calcium, indicating that
calcium is required for membrane binding.
4. Discussion
While it has been proposed previously that daptomycin forms
oligomers on membranes, this study provides the ﬁrst such
experimental evidence. Oligomerization on membranes correlates
with the presence of phosphatidylglycerol, which coincides with the
involvement of phosphatidylglycerol in bacterial susceptibility to
daptomycin [7] and suggests that the daptomycin oligomer is the
functional membrane lesion.
Our ﬁndings can be summarized in themodel of daptomycin activity
that is shown in Fig. 7. In this model, binding of calcium to daptomycin
causes a conformational change that in turn triggersmembranebinding,
or, at sufﬁciently high concentration, oligomerization in solution [16].
Membrane-bound daptomycin then interacts with phosphatidylgly-
cerol, resulting in a second conformational transition that leads to the
formation of the oligomer. We propose that the oligomer forms the
functional membrane lesion, possibly enclosing a central aperture as is
the case with many pore-forming proteins and peptides, although
differences in the rate of daptomycin-induced membrane depolariza-
tion [5] and the absence of non-speciﬁc membrane permeabilization
[24] suggest that a classic pore may not be formed.Ca
Ca
Ca
CaCa
solution
CaCa
PC membranes
Ca Ca
PC/PG membranes
PG
Ca Ca
K+
Fig. 7. Model of daptomycin oligomerization on membranes. Calcium binds to
daptomycin in solution and causes a conformational change, which at high
concentration facilitates oligomerization in solution. It also facilitates binding to PC
membranes, on which however no oligomerization occurs. On PC/PG membranes, as
well as on bacterial membranes, the interaction of daptomycin/calcium with the
negatively charged headgroup of phosphatidylglycerol induces a second conforma-
tional change that induces oligomerization and deeper membrane insertion.The key aspects of this model, in particular the roles of calcium in
membrane binding and of phosphatidylglycerol in oligomerization,
are supported by evidence; however, several details remain hypo-
thetical. The postulated changes in conformation are inferred from
those in function. The initial change triggered by calcium binding may
lead to an increased exposure of hydrophobic moieties, possibly the
N-terminal acyl chain; such a change would promote both oligomer-
ization in solution and binding to membranes. The second change,
triggered by phosphatidylglycerol, is depicted as causing not only
oligomerization but also deeper membrane penetration. Both kynur-
enine [17] and NBD in NBD–daptomycin show a greater gain of
ﬂuorescence intensity on PC/PG membranes than on PC membranes,
indicating a more hydrophobic environment on the former. However,
on PC/PG membranes, daptomycin will not only interact with
surrounding lipid molecules but also other daptomycin molecules
within the oligomer that forms only on these membranes. It should
also be noted that PC/PG membranes may be subject to lateral phase
segregation, which is further promoted by calcium ions. If this occurs,
membranes may become leaky, which may expose additional sites for
hydrophobic interaction. For these reasons, the increase in environ-
mental hydrophobicity cannot be unequivocally ascribed to deeper
membrane penetration.
In Fig. 7, the interaction of daptomycin with phosphatidylglycerol
is assumed to be mediated by calcium. Daptomycin has only one
intrinsic positive charge, which is the amino group in the side chain of
the ornithine residue. With NBD–daptomycin, as well as with
previously characterized ornithine-modiﬁed derivatives [25,26],
even this single charge is masked (see Fig. 1); nevertheless, these
derivatives retain antimicrobial activity, which leaves calcium as the
only available positive charge available to interact with the negative
charge of phosphatidylglycerol. Not many more conclusions can be
drawn as to the structure of the oligomer, other than that it is fairly
stable on a time scale of minutes to hours, as indicated by the experi-
ment shown in Fig. 4B. The structure of the membrane-associated
oligomer thus remains to be determined.
Regarding the experimental strategies used in this study, it should
be noted that FRET between daptomycin (or Alexa Fluor 350–
daptomycin) and NBD–daptomycin can be quite extensive even in
the absence of oligomerization, as is evident from Figs. 4A, B and 5C, D.
The extent of FRET will also vary with the ratio of total daptomycin to
membrane lipids, and it will also be affected by uneven distribution of
membrane-bound daptomycin, as has been demonstrated by ﬂuores-
cence with bacterial cells [8]. In contrast, the relief of self-quenching
of NBD–daptomycin, caused by the addition of unlabeled daptomycin,
is much less sensitive to such inﬂuences, as long as the amount of
NBD–daptomycin remains constant. Without oligomerization, the
addition of unlabeled daptomycin should cause no change in
quenching, since the unlabeled daptomycin would simply not
interfere with the NBD–daptomycin in any way. In contrast, with
oligomerization, the addition of unlabeled daptomycin must reduce
quenching, since within the hybrid oligomers the NBD–daptomycin
molecules will be less likely to closely interact with one another.
Therefore, the more robust quenching assay was preferred to detect
oligomerization on bacterial membranes.
In summary, we have shown that daptomycin oligomerizes on
liposomal and bacterial membranes. The requirements for oligomer-
ization resemble those established for membrane permeabilization,
suggesting that the oligomer is the functional membrane lesion. The
detailed structure of the oligomer remains to be established.
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